In agriculture, the prevention and treatment of bacterial infections represents an 10 increasing challenge. Traditional (chemical) methods have been restricted to ensure public health 11 and limit the occurrence of resistant strains. Bacteriophages could be a sustainable alternative. A 12 major hurdle towards the commercial implementation of phage-based biocontrol strategies 13 concerns aspects of regulation and intellectual property protection. Within this study, two datasets 14 have been composed to analyze both scientific publications and patent documents and to get an 15 idea on the focus of R&D by means of an abstract and claim analysis. 137 papers and 49 patent 16 families were found searching public databases, their numbers increasing over time. Within this 17 dataset, the majority of the patent documents were filed by non-profit organizations in Asia. There 18 seems to be a good correlation between the papers and patent documents in terms of targeted 19 bacterial genera. Furthermore, granted patents seem to claim rather broad and cover methods of 20 treatment. This review shows that there is indeed a growing publishing and patenting activity 21 concerning phage biocontrol. Targeted research is needed to further stimulate the exploration of 22 phages within integrated pest management strategies and to deal with bacterial infections in crop 23 production. 24 25 26 29 the first applications of phages focused on human medicine [3], other fields including agriculture 30 soon began to explore the potential of bacteriophages as biocontrol agents [4]. The first isolation of 31 phages infecting plant pathogenic bacteria (PPB) dates back to 1924, when it was shown that 32 Xanthomonas campestris pv. campestris, causing black rot in Brassicaceae, could be lysed by the filtrate 33 of diseased cabbages [4,5]. The following years, interest in phages as biocontrol agents remained 34 relatively high [4]. However, the discovery of broad-spectrum antibiotics and other bactericidal 35 chemicals resulted in a dwindling interest in phage therapy research in general [6].
Introduction

27
Soon after the discovery of bacteriophages by d'Herelle and Twort at the beginning of the 20 th 28 century [1,2], the potential to use these bacterial viruses as a therapeutic was recognized. Although the Council of 21 October 2009) [15] . These strategies are based on the implementation of sustainable attributed application number has been chosen to represent the family. Within the database, the 146 families comprise in total 97 patents and applications (both active and non-active). Figure 1 shows 147 the different patent families organized per year (priority year -dark blue area chart). It shows that 148 the number of patent families slightly increases in time (peak at 2013) and decreases again as less 149 patents have been filed in 2016. Information on patent applications from 2017, 2018 and 2019 is not 150 complete as these applications may not have been published yet.
151
In sharp contrast, 137 scientific publications 
158
When looking at the patent documents in more detail (Figure 1 -bar charts) , a distinction should 159 be made between "Granted", "Pending" and "Dead", based on their legal status as derived from 160 Espacenet. In total, 59 patents and patent applications (61%) are active -22 patents (23%) have been 161 granted, 37 applications (38%) are pending -and 38 patent documents (39%) can be considered dead.
162
From the latter 39% are applications that were deemed to be withdrawn, 16% are rejected applications 163 and 16% are lapsed patents. Figure 1 shows an overview of the percentages granted, pending and 164 dead documents with the same priority year. The first active patent from the dataset dates from 2004 165 (JP4532959 (B2)). In 2011 there were two families filed, represented by GB20110010647 and 166 JP20110102153, containing in total six patents and four applications respectively. All the applications 167 and patents within the first family remain active -50% is granted and 50% is pending -whereas two 168 out of four patent applications from the latter family have been rejected. 2012 has the most patents, 169 26 in total, divided among four different families represented by GB20120017097, KR101584214, 170 MX2012011440 and US201261716245. This last family contains four granted patents and sixteen 171 applications. The family represented by GB20120017097 consists of one pending and two dead 172 applications and one granted patent (US9278141 (B2)). In 2013, there was a peak in the amount of 173 patent families filed as the number reached nine families. These families consist in total of ten 174 applications which are all dead. The majority of these applications were deemed to be withdrawn 175 (80%), meaning that the designation fee was not paid. year: green ("Granted patents") corresponds to the number of granted patents, yellow ("Pending 183 applications") pending applications and grey ("Dead applications and patents") dead patents and 184 applications. This last group consists of patents and applications that are abandoned, refused, 185 withdrawn, deemed to be withdrawn or patents that are lapsed.
186
Applicants and geographical distribution 187 Analyzing the applicants of the different patent documents, it shows that 56% (54) of the 97 188 patent documents have been filed by academia, whereas 37% (36) are linked to industry (without 189 joint applicants) and 7% (7) are joint applicants. This means that the family, or patent documents 190 belonging to a family, have more than one applicant and thus the rights of the patent are distributed 191 among the different partners. The most prominent academic applicants based on the amount of 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 applications is also visible among the European -54% (7/13) -and among the North American 208 documents -44% (7/16). Only 8% (1/13) of European patents are granted, while this is 25% (4/16) of 209 the North American patents. The amount of pending applications is similar as 38% (5/13) and 31% 210 (5/16) of the European and North American applications are pending, respectively. On the other 211 hand, in case of the South American patent applications, 89% (8/9) is pending and 11% is dead.
212
Notably is that 7/9 of these South American patents are part of the same patent family 213 (US2016309723).
214
Furthermore, China has the highest percentage of dead patents with 63% (12/19). The majority 215 of these patent were deemed to be withdrawn after the admission fee was not paid (92%). On the 216 contrary, Japan and Korea have the highest amount of granted patents, 38% (5/13) and 67% (6/9) of 217 the patents filed are granted and still active respectively. 
318
When evaluating the 77 independent claims of all active, granted patents, the majority of the 319 claims are process claims protecting different methods to use phages as a treatment for bacterial 320 infection (40% - Supplementary Figure 1) . Furthermore, this data shows that 30% of the claims protect 321 the composition of the phage product. This means that a combination of phages is protected and/or 322 the formulation of the final product. 19% can be considered as compound claims as the claim is 323 protecting the phage(s) as an active ingredient and only 10% of the claims are production claims.
324
The 77 independent claims have also been categorized within three classes: 
349
-JP6391579).
350
The claims categorized as "Phage claims" are generally narrow defined (41%) as the claims 351 protect the phage and its genomic sequence. However, highly similar phages with differences in their 352 genomic sequence fall outside the scope of these claim. Thus, the claims can be circumvented. A 353 judge, however, may interpret by the claim as equivalent by doctrine of equivalence. The isolation of 354 a different phage that targets the same bacterium also circumvents the claim . On the other hand, the 355 majority of the "Composition claims" and "Production claims" are difficult to circumvent as they are 356 broadly defined (56% and 75% respectively).
357
As mentioned above, four out of 21 granted patents have been filed by a private organization 358 (Fixed Phage) and these patents belong to the same patent family. When looking at the claims for 359 these patents, one notices that all the claims are broadly defined. As the invention discusses the use 360 of phages in a composition to fight bacterial infections without defining the phage itself, the majority 361 of the claims protect the composition of the product rather than the phage or the production of the 362 product.
363 
394
The assessment of the legal status of the documents shows a high fraction of dead documents 395 (39%). Within this group of dead applications, 16% of the applications have been rejected as the 396 invention was not considered novel (US2009053179) and/or did not include an inventive step 397 (JP2005073562). The majority of the dead documents are applications that were deemed to be 398 withdrawn (39%) and patents that are lapsed (16% -no oppositions were filed e.g. EP0182106). In 399 both cases, the applicants did not pay the fees needed to maintain the rights of the patent. For some 400 patent applications this is due to a negative search report (GB2519913 and WO2007044428) in which . Notably, none of these products or phages have been found by the authors in the public 425 assessed databases. This may imply that the patents could be licensed (e.g. from an academic 426 partner), the applications are not publicly available yet or the product is not patented opening the 427 discussion whether patenting is indeed crucial for commercial activities of phage applications in 428 agriculture.
429
Efforts in Asia to protect phage biocontrol preparations
430
The geographical distribution of the patent documents ( Figure 2) shows that the majority was 
462
As Figure 3 shows, there is a discrepancy within the "Other" group. This category combines
463
documents that talk about other bacterial genera or do not specify the bacterium that is being 464 addressed. The majority of the patents and patent applications have been classified in this category 465 since these do not specify a particular bacterial genus. From these patent documents, we observe that 466 all the granted patents filed by industrial applicants have chosen this option (Table 1) 
471
Granted patents include broad claims
472
The main focus of the scientific publications and the granted patents indicate a difference in 473 emphasis (Figure 4 ). While the majority of the manuscripts discuss the isolation of one or more 474 bacteriophages and their basic characterization, the majority of the patents claim a method of treating 475 a bacterial infection by means of a phage product. Only 39% of scientific papers address the latter 476 although this could be considered as the ultimate goal of phage biocontrol. This illustrates that first 477 efforts are made in the field but that there are still opportunities for further innovations.
478
Limited efforts have been made towards patenting detection strategies for and by phages in the 479 field of phage biocontrol in crop production. Since phages are highly specific to a specific bacterium 480 and can locate their host in a complex matrix of bacteria they can easily be used as a detection tool
481
[40]. However, this study suggests that little published evidence is available done in this area by both 482 the scientific community and the industrial early adopters as there are no claims protecting possible 483 methods of detection and only a small minority (8%) of scientific papers discuss this matter.
484
The claims that belong to the "Phage" category consist of claims that protect a natural occurring 496 Figure 4 also shows that there is limited evidence on the optimization of the production of phage 497 cocktails based on both scientific and patent literature. One could argue that the production of phages 498 is phage dependent (specific bacterial strains, media, temperature) and thus keeping the production 499 of phages secret could be a valid strategy to maintain a competitive edge [18] .
500
On the other hand, many patents claim the combination of phages or phages as part of a 501 formulation. This is illustrated by Supplementary Figure 1 . 
